Data updated: Mar 10, 2026
EGRIFTA
TESAMORELIN ACETATE
Approved 2010-11-10
1
Indication
--
Phase 3 Trials
15
Years on Market
Details
- Status
- Prescription
- First Approved
- 2010-11-10
- Routes
- SUBCUTANEOUS
- Dosage Forms
- POWDER
EGRIFTA Approval History
Loading approval history...
What EGRIFTA Treats
1 indicationsEGRIFTA is approved for 1 conditions since its original approval in 2010. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Lipodystrophy
Source: FDA Label
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EGRIFTA FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.